PAI
MRSN

ProQuest Associates IV’s Mersana Therapeutics MRSN Stock Holding History

ProQuest Associates IV’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$9.56M Hold
38,228
– – 18.05% 2
2018
Q2 		$17.1M Hold
38,228
– – 26.27% 2
2018
Q1 		$15.1M Hold
38,228
– – 17.33% 2
2017
Q4 		$15.7M Hold
38,228
– – 20.86% 2
2017
Q3 		$16.5M Hold
38,228
– – 16.55% 3
2017
Q2 		$13.4M Buy
+38,228
New +$13.2M 17.07% 4

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

ProQuest Associates IV's MRSN Position: Q3 2018 in Review

ProQuest Associates IV held its Mersana Therapeutics (MRSN) position steady in Q3 2018 at 38,228 shares worth $9.56M. The position accounts for 18.05% of the portfolio, ranked #2.

ProQuest Associates IV first reported a position in MRSN in Q2 2017 and has held it in 6 quarters since. The position peaked at $17.1M in Q2 2018. 46 funds tracked by Wall St. Rank hold MRSN as of Q3 2018.

  • ProQuest Associates IV held 38,228 shares of Mersana Therapeutics worth $9.56M as of Q3 2018.
  • ProQuest Associates IV left its Mersana Therapeutics share count unchanged in Q3 2018.
  • Mersana Therapeutics made up 18.05% of ProQuest Associates IV's portfolio in Q3 2018, its #2 holding.
  • ProQuest Associates IV first reported a position in Mersana Therapeutics in Q2 2017 and has held it in 6 quarters since.
  • ProQuest Associates IV's Mersana Therapeutics position peaked at $17.1M in Q2 2018.
  • 46 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2018.

Based on ProQuest Associates IV's 13F filing for Q3 2018, filed 14 Nov 2018.